Determinants and consequences of M&A activity in the pharmaceutical – biotechnological industry

Alisher Saydalikhodjayev
March 30, 2008
Industrial Organization
Professor J. Likens

ABSTRACT
Traditionally, pharmaceutical firms with large R&D platforms dominated the space of drug innovation; however, the last 30 years produced a large number of smaller research-oriented biotech firms. Advances in the human genome project opened doors to the field of drug innovation to many new players. This event caused a change in the structure of the pharmaceutical-biotech industry, primarily through a hike in M&A activity during the 80’s and the 90’s. The examined study found that large pharmaceutical firms that had gaps in their drug development pipeline tended to engage in acquisitions, while small biotech firms that experienced financial trouble tended to participate in M&A as targets. At the same time, small biotech firms that had promising drug development pipelines and healthy......

Join Now to view the rest of this term paper!
Members: Login to view this research paper.

Title: M&A In Biotech Industry
Approximate Word Count: 6740
Approximate Pages: 27 (250 words per double-spaced page)

With the Term Papers Lab Membership Pass, you get instant access to every essay on this site, including this essay on M&A In Biotech Industry, for as long as you remain a member.

Other essays sites charge almost $100 for a single term paper. At Term Papers Lab, you can get instant access to over 100,000 research papers for as little as $29.95!